$CHRS
Coherus BioSciences, Inc. Stock $chrs

$chrs Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000156459020007416 Filed on February 27, 2020

Income Statement

Concept	2019 Q4	2019 Q3	2019 Q2
Revenue	$123.9M	$111.7M	$83.43M
YoY Change
Cost Of Revenue	$7.800M	$6.400M	$601.0K
YoY Change
Gross Profit	$116.1M	$105.2M	$82.83M
YoY Change
Gross Profit Margin	93.7%	94.23%	99.28%
Selling, General & Admin	$36.10M	$31.83M	$36.46M
YoY Change	6.8%	25.46%	98.23%
% of Gross Profit	31.11%	30.24%	44.01%
Research & Development	$34.90M	$21.57M	$18.88M
YoY Change	30.71%	-31.75%	-28.79%
% of Gross Profit	30.07%	20.49%	22.8%
Depreciation & Amortization	$1.100M	$800.0K	$700.0K
YoY Change	83.33%	0.0%	-22.22%
% of Gross Profit	0.95%	0.76%	0.85%
Operating Expenses	$78.82M	$59.84M	$55.94M
YoY Change	30.28%	5.04%	24.56%
Operating Profit	$37.23M	$51.84M	$27.49M
YoY Change			-161.22%
Interest Expense	-$4.500M	$4.469M	$4.433M
YoY Change	87.5%	84.29%	-284.71%
% of Operating Profit	-12.09%	8.62%	16.12%
Other Income/Expense, Net	$700.0K	$518.0K	$558.0K
YoY Change	133.33%	-9.28%	-84.5%
Pretax Income	$41.30M	$47.89M	$23.62M
YoY Change	-165.97%	-181.41%	-154.06%
Income Tax	$2.000M	$800.0K	$51.00K
% Of Pretax Income	4.84%	1.67%	0.22%
Net Earnings	$39.23M	$47.04M	$23.57M
YoY Change	-162.67%	-179.99%	-154.01%
Net Earnings / Revenue	31.67%	42.12%	28.25%
Basic Earnings Per Share	$0.56	$0.67	$0.34
Diluted Earnings Per Share	$0.53	$0.63	$0.32
COMMON SHARES
Basic Shares Outstanding		69.88M	69.48M
Diluted Shares Outstanding		78.53M	72.96M

Balance Sheet

Concept	2019 Q4	2019 Q3	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$177.7M	$170.5M	$111.9M
YoY Change	145.44%	45.48%	-29.97%
Cash & Equivalents	$177.7M	$165.1M	$105.9M
Short-Term Investments		$5.400M	$6.000M
Other Short-Term Assets	$13.50M	$8.600M	$12.00M
YoY Change	16165.06%	-34.35%	-7.69%
Inventory	$9.807M	$7.668M	$4.333M
Prepaid Expenses
Receivables	$142.0M	$89.60M	$77.40M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$343.0M	$276.4M	$205.6M
YoY Change	306.25%	112.11%	19.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.840M	$5.857M	$5.646M
YoY Change	-12.31%	-13.87%	-49.59%
Goodwill	$943.0K	$943.0K	$943.0K
YoY Change	0.0%
Intangibles	$2.620M	$2.620M	$2.620M
YoY Change	0.0%
Long-Term Investments
YoY Change
Other Assets	$362.0K	$514.0K	$14.00K
YoY Change	2485.71%	-35.75%	-98.25%
Total Long-Term Assets	$65.92M	$51.01M	$34.83M
YoY Change	338.46%	355.43%	124.68%
TOTAL ASSETS
Total Short-Term Assets	$343.0M	$276.4M	$205.6M
Total Long-Term Assets	$65.92M	$51.01M	$34.83M
Total Assets	$408.9M	$327.4M	$240.5M
YoY Change	311.12%	131.37%	27.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$25.99M	$13.71M	$19.22M
YoY Change	69.9%	80.38%	44.53%
Accrued Expenses	$17.26M	$16.47M	$8.295M
YoY Change	146.26%	-0.16%	-2.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$115.0M	$82.70M	$61.23M
YoY Change	245.66%	237.56%	175.82%
LONG-TERM LIABILITIES
Long-Term Debt	$178.4M	$177.8M	$177.2M
YoY Change	73.04%	73.13%	73.22%
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$115.0M	$82.70M	$61.23M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$303.7M	$271.4M	$244.4M
YoY Change	119.99%	110.19%	93.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$895.0M		-$981.3M
YoY Change	-9.12%
Common Stock	$1.001B		$977.8M
YoY Change	5.73%		5.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$105.2M	$56.00M	-$4.000M
YoY Change
Total Liabilities & Shareholders Equity	$408.9M	$327.4M	$240.5M
YoY Change	311.12%	131.38%	27.7%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2019 Q2
OPERATING ACTIVITIES
Net Income	$39.23M	$47.04M	$23.57M
YoY Change	-162.67%	-179.99%	-154.01%
Depreciation, Depletion And Amortization	$1.100M	$800.0K	$700.0K
YoY Change	83.33%	0.0%	-22.22%
Cash From Operating Activities	$17.80M	$54.90M	$12.70M
YoY Change	-137.55%	-228.27%	-135.77%
INVESTING ACTIVITIES
Capital Expenditures	-$400.0K	-$900.0K	-$200.0K
YoY Change	100.0%	80.0%
Acquisitions
YoY Change
Other Investing Activities	-$5.700M	$700.0K	$9.000M
YoY Change	-135.63%	-94.74%	-154.22%
Cash From Investing Activities	-$6.000M	-$300.0K	$8.800M
YoY Change	-137.97%	-102.34%	-153.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.200M	3.700M	3.000M
YoY Change	-53.85%	270.0%	-97.0%
NET CHANGE
Cash From Operating Activities	17.80M	54.90M	12.70M
Cash From Investing Activities	-6.000M	-300.0K	8.800M
Cash From Financing Activities	1.200M	3.700M	3.000M
Net Change In Cash	13.00M	58.30M	24.50M
YoY Change	-144.83%	-301.03%	-48.74%
FREE CASH FLOW
Cash From Operating Activities	$17.80M	$54.90M	$12.70M
Capital Expenditures	-$400.0K	-$900.0K	-$200.0K
Free Cash Flow	$18.20M	$55.80M	$12.90M
YoY Change	-138.56%	-231.91%	-136.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q2	dei	Entity Public Float EntityPublicFloat	1400000000
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70624365
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M20D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y7M20D
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	001-36721
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3615821
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	333 Twin Dolphin Drive
CY2019	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
CY2019	dei	City Area Code CityAreaCode	650
CY2019	dei	Local Phone Number LocalPhoneNumber	649 - 3530
CY2019	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	7000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1000763000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	946515000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-558000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-282000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-894998000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-984831000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	105214000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	408927000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	99467000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	89833000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-209339000
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.29
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.22
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.48
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.23
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.22
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.48
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65034827
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53133620
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53133620
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177668000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72356000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50000
CY2019Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	141992000
CY2018Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	0
CY2019Q4	us-gaap	Inventory Net InventoryNet	9807000
CY2018Q4	us-gaap	Inventory Net InventoryNet	1659000
CY2019Q4	chrs	Prepaid Manufacturing Expense Current PrepaidManufacturingExpenseCurrent	8578000
CY2018Q4	chrs	Prepaid Manufacturing Expense Current PrepaidManufacturingExpenseCurrent	7906000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4964000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2462000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	343009000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	84433000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5840000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6660000
CY2019Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	45264000
CY2018Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	4012000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10649000
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2620000
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2620000
CY2019Q4	us-gaap	Goodwill Goodwill	943000
CY2018Q4	us-gaap	Goodwill Goodwill	943000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	240000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	785000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	362000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14000
CY2019Q4	us-gaap	Assets Assets	408927000
CY2018Q4	us-gaap	Assets Assets	99467000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	25985000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15294000
CY2019Q4	chrs	Accrued Rebates Fees And Reserve Current AccruedRebatesFeesAndReserveCurrent	51120000
CY2018Q4	chrs	Accrued Rebates Fees And Reserve Current AccruedRebatesFeesAndReserveCurrent	0
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18410000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10540000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17258000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7008000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2196000
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	419000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	114969000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33261000
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	102000
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	60000
CY2019Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	78542000
CY2018Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	77319000
CY2019Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	26181000
CY2018Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	25773000
CY2019Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	73663000
CY2018Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	0
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10256000
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1645000
CY2019Q4	us-gaap	Liabilities Liabilities	303713000
CY2018Q4	us-gaap	Liabilities Liabilities	138058000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70366661
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70366661
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	7000
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-38591000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	356071000
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0
CY2017	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1556000
CY2019	chrs	Cost Of Sold Goods CostOfSoldGoods	17078000
CY2018	chrs	Cost Of Sold Goods CostOfSoldGoods	0
CY2017	chrs	Cost Of Sold Goods CostOfSoldGoods	0
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	110239000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	162389000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	137037000
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	94177000
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	71303000
CY2018	us-gaap	Operating Expenses OperatingExpenses	204416000
CY2017	us-gaap	Operating Expenses OperatingExpenses	233692000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-204416000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-232136000
CY2019	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	2457000
CY2018	us-gaap	Interest Expense InterestExpense	9684000
CY2017	us-gaap	Interest Expense InterestExpense	9552000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4691000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3402000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	92775000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-209409000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-238286000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2942000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Profit Loss ProfitLoss	89833000
CY2018	us-gaap	Profit Loss ProfitLoss	-209409000
CY2017	us-gaap	Profit Loss ProfitLoss	-238286000
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-70000
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-116000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69679916
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73185943
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65034827
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3259000
CY2017	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-116000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	89557000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-208871000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-238290000
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19354000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-238170000
CY2019	us-gaap	Profit Loss ProfitLoss	89833000
CY2018	us-gaap	Profit Loss ProfitLoss	-209409000
CY2017	us-gaap	Profit Loss ProfitLoss	-238286000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-276000
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	468000
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-120000
CY2019	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	89557000
CY2018	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-208941000
CY2017	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-238406000
CY2019	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0
CY2018	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-70000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	482000
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-120000
CY2017	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	116000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-238170000
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30535000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2153000
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1591000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34984000
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	468000
CY2018	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	2130000
CY2018	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	1359000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-209339000
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-38591000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5934000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3518000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35218000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-276000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	89833000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	105214000
CY2019	us-gaap	Profit Loss ProfitLoss	89833000
CY2018	us-gaap	Profit Loss ProfitLoss	-209409000
CY2017	us-gaap	Profit Loss ProfitLoss	-238286000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3235000
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3398000
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	42000
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3230000
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2260000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	33591000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	34797000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	33397000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	165000
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	301000
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	156000
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2339000
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1484000
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1352000
CY2019	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-110000
CY2018	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-3861000
CY2018	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	300000
CY2019	chrs	Payments To Acquire Interest In Related Party PaymentsToAcquireInterestInRelatedParty	0
CY2017	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-558000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	410000
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	0
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	0
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-51000
CY2019	chrs	Non Cash Bonus Payment Settled In Common Stock NonCashBonusPaymentSettledInCommonStock	0
CY2018	chrs	Non Cash Bonus Payment Settled In Common Stock NonCashBonusPaymentSettledInCommonStock	0
CY2017	chrs	Non Cash Bonus Payment Settled In Common Stock NonCashBonusPaymentSettledInCommonStock	2668000
CY2019	chrs	Non Cash Manufacturing Postponement Fee Settled In Common Stock NonCashManufacturingPostponementFeeSettledInCommonStock	0
CY2018	chrs	Non Cash Manufacturing Postponement Fee Settled In Common Stock NonCashManufacturingPostponementFeeSettledInCommonStock	0
CY2017	chrs	Non Cash Manufacturing Postponement Fee Settled In Common Stock NonCashManufacturingPostponementFeeSettledInCommonStock	4125000
CY2019	chrs	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	1789000
CY2018	chrs	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	0
CY2017	chrs	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	0
CY2019	chrs	Upfront And Milestone Expense Related To License And Collaboration Arrangements UpfrontAndMilestoneExpenseRelatedToLicenseAndCollaborationArrangements	11075000
CY2018	chrs	Upfront And Milestone Expense Related To License And Collaboration Arrangements UpfrontAndMilestoneExpenseRelatedToLicenseAndCollaborationArrangements	0
CY2017	chrs	Upfront And Milestone Expense Related To License And Collaboration Arrangements UpfrontAndMilestoneExpenseRelatedToLicenseAndCollaborationArrangements	0
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	141992000
CY2018	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	0
CY2017	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	0
CY2019	chrs	Increase Decrease In Receivables From Collaboration And License Agreement IncreaseDecreaseInReceivablesFromCollaborationAndLicenseAgreement	0
CY2018	chrs	Increase Decrease In Receivables From Collaboration And License Agreement IncreaseDecreaseInReceivablesFromCollaborationAndLicenseAgreement	0
CY2017	chrs	Increase Decrease In Receivables From Collaboration And License Agreement IncreaseDecreaseInReceivablesFromCollaborationAndLicenseAgreement	-1859000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	48184000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5484000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	672000
CY2018	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-7063000
CY2017	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-7788000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2126000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1146000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11014000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	348000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1000
CY2017	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0
CY2019	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	9893000
CY2018	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-301000
CY2017	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3810000
CY2019	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0
CY2018	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-233000
CY2017	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-644000
CY2019	chrs	Increase Decrease In Accrued Rebates Fees And Reserve IncreaseDecreaseInAccruedRebatesFeesAndReserve	51120000
CY2018	chrs	Increase Decrease In Accrued Rebates Fees And Reserve IncreaseDecreaseInAccruedRebatesFeesAndReserve	0
CY2017	chrs	Increase Decrease In Accrued Rebates Fees And Reserve IncreaseDecreaseInAccruedRebatesFeesAndReserve	0
CY2019	chrs	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	10035000
CY2018	chrs	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	8466000
CY2017	chrs	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-4871000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	10386000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	69000
CY2017	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-14079000
CY2019	chrs	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-2010000
CY2018	chrs	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	0
CY2017	chrs	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	0
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0
CY2017	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1562000
CY2019	chrs	Increase Decrease In Advance Payments Under License Agreement IncreaseDecreaseInAdvancePaymentsUnderLicenseAgreement	0
CY2018	chrs	Increase Decrease In Advance Payments Under License Agreement IncreaseDecreaseInAdvancePaymentsUnderLicenseAgreement	0
CY2017	chrs	Increase Decrease In Advance Payments Under License Agreement IncreaseDecreaseInAdvancePaymentsUnderLicenseAgreement	-1070000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-30000
CY2018	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0
CY2017	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	75000000
CY2019	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	72955000
CY2018	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0
CY2017	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-428000
CY2017	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	242000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	28355000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-159266000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-200286000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1822000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	789000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4573000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	20235000
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	42869000
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	74344000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	20400000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	43170000
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	74500000
CY2019	chrs	Upfront And Milestone Payments Related To License And Collaboration Arrangements UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements	11075000
CY2018	chrs	Upfront And Milestone Payments Related To License And Collaboration Arrangements UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements	0
CY2017	chrs	Upfront And Milestone Payments Related To License And Collaboration Arrangements UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements	0
CY2019	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0
CY2017	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0
CY2018	chrs	Payments To Acquire Interest In Related Party PaymentsToAcquireInterestInRelatedParty	400000
CY2017	chrs	Payments To Acquire Interest In Related Party PaymentsToAcquireInterestInRelatedParty	0
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12732000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1188000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4417000
CY2019	chrs	Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsCommissionsAndOfferingCosts	8153000
CY2018	chrs	Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsCommissionsAndOfferingCosts	101748000
CY2017	chrs	Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsCommissionsAndOfferingCosts	131305000
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5558000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2082000
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	482000
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3519000
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1591000
CY2017	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	815000
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2017	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	89370000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	105421000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	206787000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-276000
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	468000
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-120000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	104717000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-54565000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1964000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73191000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	127756000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	125792000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	177908000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73191000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	127756000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	15263000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	8200000
CY2017	us-gaap	Interest Paid Net InterestPaidNet	8200000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1732000
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0
CY2019	chrs	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	999000
CY2018	chrs	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	272000
CY2017	chrs	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities	77000
CY2019	chrs	Non Cash Minority Interest Reflected In Additional Paid In Capital NonCashMinorityInterestReflectedInAdditionalPaidInCapital	0
CY2018	chrs	Non Cash Minority Interest Reflected In Additional Paid In Capital NonCashMinorityInterestReflectedInAdditionalPaidInCapital	1359000
CY2017	chrs	Non Cash Minority Interest Reflected In Additional Paid In Capital NonCashMinorityInterestReflectedInAdditionalPaidInCapital	0
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5267000
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2017	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2019	chrs	Non Cash Employee Bonus Settled In Common Stock NonCashEmployeeBonusSettledInCommonStock	1350000
CY2018	chrs	Non Cash Employee Bonus Settled In Common Stock NonCashEmployeeBonusSettledInCommonStock	0
CY2017	chrs	Non Cash Employee Bonus Settled In Common Stock NonCashEmployeeBonusSettledInCommonStock	2668000
CY2019	chrs	Common Stock Offering Costs Included In Accounts Payable And Accrued Liabilities CommonStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities	0
CY2018	chrs	Common Stock Offering Costs Included In Accounts Payable And Accrued Liabilities CommonStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities	75000
CY2017	chrs	Common Stock Offering Costs Included In Accounts Payable And Accrued Liabilities CommonStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities	115000
CY2019	chrs	Manufacturing Services Settled In Common Stock ManufacturingServicesSettledInCommonStock	0
CY2018	chrs	Manufacturing Services Settled In Common Stock ManufacturingServicesSettledInCommonStock	0
CY2017	chrs	Manufacturing Services Settled In Common Stock ManufacturingServicesSettledInCommonStock	6810000
CY2019	us-gaap	Nature Of Operations NatureOfOperations	<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p id="Notes_to_Consolidated" style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:10pt;">Organization and Operations </p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Description of the Business </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coherus BioSciences, Inc. (the “Company” or “Coherus”) is a commercial-stage biotherapeutics company, focused on the global biosimilar market. Biosimilars are a class of protein-based therapeutics with high similarity to approved originator products on the basis of various structural, physicochemical and biological properties, as well as in terms of safety and efficacy. The Company’s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 25, 2018, the Company received regulatory approval for the marketing of UDENYCA<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, from the European Commission, and received regulatory approval for UDENYCA<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> from the U.S. Food and Drug Administration (“FDA”) on November 2, 2018. The Company initiated U.S. sales of UDENYCA<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup> on January 3, 2019.</p>
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-895000000.0
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177700000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	89800000
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures reported in the financial statements. Management uses significant judgment when making estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determing the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sale allowances, as well as milestones included in collaboration and license arrangements; related to its stock-based compensation, valuation of deferred tax assets, impairment of goodwill and long-lived assets, the valuation of acquired intangible assets, valuation and reserves for inventory, clinical trial accruals, contingent consideration, convertible notes valuation, as well as certain accrued liabilities. Management bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain and the actual results could differ from these estimates. </p>
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-209339000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-238170000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	239000
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-571000
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	52000
CY2019	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	356071000
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0
CY2017	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1556000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177668000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72356000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126911000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50000
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	60000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	240000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	785000
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	785000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177908000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73191000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127756000
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains its cash in bank accounts, which at times exceed federally insured limits. The Company attempts to minimize the risks related to cash, cash equivalents and restricted cash by investing in money markets with a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company’s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company also maintains restricted cash in money market funds that invest primarily in U.S. Treasury securities. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash and money market funds. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to credit risk from trade receivables related to the product sales in the United States. To date, the Company has not experienced significant losses with respect to the collection of trade receivables. The Company believes that its allowance for doubtful accounts was adequate at December 31, 2019.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into a strategic commercial supply agreement with KBI Biopharma (“KBI”) for the supply of <span style="color:#000000;">UDENYCA<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup>. The Company currently has not engaged back-up suppliers or vendors for this single-sourced service. If KBI is not able to manufacture the supply needed in the quantities and timeframe required, the Company may not be able to supply the </span>product in a timely manner.</p>
CY2019	chrs	Write Off Of Prepaid Manufacturing Costs WriteOffOfPrepaidManufacturingCosts	1300000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	400000
CY2019	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	4500000
CY2018	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2800000
CY2017	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	0
CY2019	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
CY2019Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2018Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7200000
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9200000
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2019	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3	0
CY2018	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3	0
CY2019	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3	0
CY2018	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3	0
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5089000
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2851000
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	43446000
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1576000
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6536000
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1244000
CY2019Q4	us-gaap	Inventory Gross InventoryGross	55071000
CY2018Q4	us-gaap	Inventory Gross InventoryGross	5671000
CY2019Q4	us-gaap	Inventory Net InventoryNet	9807000
CY2018Q4	us-gaap	Inventory Net InventoryNet	1659000
CY2019Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	45264000
CY2018Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	4012000
CY2019Q4	chrs	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	55071000
CY2018Q4	chrs	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	5671000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22136000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19697000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16296000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13037000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5840000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6660000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3300000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3200000
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3400000
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	100000
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	3900000
CY2017	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	600000
CY2019Q4	chrs	Accrued Clinical And Manufacturing Liabilities Current AccruedClinicalAndManufacturingLiabilitiesCurrent	7106000
CY2018Q4	chrs	Accrued Clinical And Manufacturing Liabilities Current AccruedClinicalAndManufacturingLiabilitiesCurrent	3950000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10152000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3058000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17258000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7008000
CY2018Q4	chrs	Reserve For Discounts And Allowances Constitute Variable Consideration ReserveForDiscountsAndAllowancesConstituteVariableConsideration	0
CY2019	chrs	Reserve For Sales Discounts And Allowances Constitute Variable Consideration ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration	344486000
CY2019	chrs	Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration	257339000
CY2019Q4	chrs	Reserve For Discounts And Allowances Constitute Variable Consideration ReserveForDiscountsAndAllowancesConstituteVariableConsideration	87147000
CY2019Q3	chrs	Additional Area Of Real Estate Property Leased AdditionalAreaOfRealEstatePropertyLeased	7448
CY2019Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	47789
CY2019Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	25011000
CY2019Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	30991000
CY2019Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	8403000
CY2019Q4	us-gaap	Purchase Obligation PurchaseObligation	64405000
CY2015Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	40341
CY2019	chrs	Number Of Laboratory Facility Structure NumberOfLaboratoryFacilityStructure	2
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2196000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10256000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	12452000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	2700000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3141000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3173000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3034000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3171000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2614000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17811671
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.582
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	93797000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	10699012
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	14.456
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	65412000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.52
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.77
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.70
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10300000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4900000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2100000
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	56400000
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15133000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2681000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	12452000
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.082
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	2400000
CY2018	us-gaap	Operating Lease Expense OperatingLeaseExpense	2200000
CY2017	us-gaap	Operating Lease Expense OperatingLeaseExpense	2300000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2660000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2695000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2672000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2518000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	10545000
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	230795
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14674553
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.202
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5328500
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.137
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	863940
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.869
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1327442
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.630
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17811671
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.582
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	33591000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34797000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	33397000
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1735000
CY2018	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0
CY2017	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0
CY2019	us-gaap	Defined Contribution Plan Plan Name DefinedContributionPlanPlanName	401(k) Plan
CY2019	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.99
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2019	chrs	Defined Contribution Plan Employer Matching Contribution Of Each Participants Contribution Plan DefinedContributionPlanEmployerMatchingContributionOfEachParticipantsContributionPlan	6000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	800000
CY2017	us-gaap	Restructuring Charges RestructuringCharges	3600000
CY2018Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	2100000
CY2019Q4	us-gaap	Restructuring Reserve RestructuringReserve	0
CY2018Q4	us-gaap	Restructuring Reserve RestructuringReserve	0
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	92584000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-208843000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-222674000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	190000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-496000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-15496000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	92774000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-209339000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-238170000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2942000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2942000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0151
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0016
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2942000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2900000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0080
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0004
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0005
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0221
CY2019	chrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0064
CY2018	chrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0015
CY2017	chrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0019
CY2019	chrs	Effective Income Tax Rate Reconciliation Tax Expense And Credits Research EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch	-0.0477
CY2018	chrs	Effective Income Tax Rate Reconciliation Tax Expense And Credits Research EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch	0.0261
CY2017	chrs	Effective Income Tax Rate Reconciliation Tax Expense And Credits Research EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch	0.0210
CY2019	chrs	Effective Income Tax Rate Reconciliation Change In Tax Reform Tax Rate EffectiveIncomeTaxRateReconciliationChangeInTaxReformTaxRate	0
CY2018	chrs	Effective Income Tax Rate Reconciliation Change In Tax Reform Tax Rate EffectiveIncomeTaxRateReconciliationChangeInTaxReformTaxRate	0
CY2017	chrs	Effective Income Tax Rate Reconciliation Change In Tax Reform Tax Rate EffectiveIncomeTaxRateReconciliationChangeInTaxReformTaxRate	-0.3690
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0055
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0223
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0021
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1444
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2610
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0194
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0317
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	138663000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	168753000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	43879000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	39891000
CY2019Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	7230000
CY2018Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	7901000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	22807000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	17123000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	7137000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	0
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	6927000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	3942000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	226643000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	237610000
CY2019Q4	chrs	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2396000
CY2019Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	589000
CY2018Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	552000
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2985000
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	552000
CY2019Q4	chrs	Deferred Tax Asset Liability Net DeferredTaxAssetLiabilityNet	223658000
CY2018Q4	chrs	Deferred Tax Asset Liability Net DeferredTaxAssetLiabilityNet	237058000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	223658000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	237058000
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-13400000
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	54600000
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4600000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18115000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15682000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18682000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1206000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1276000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3387000
CY2019	chrs	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-7718000
CY2018	chrs	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	1157000
CY2017	chrs	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-6387000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11603000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18115000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15682000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11600000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18100000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15700000
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2017	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2019	us-gaap	Net Income Loss NetIncomeLoss	89833000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-209339000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-238170000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69679916
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65034827
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53133620
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.29
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.22
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.48
CY2019	us-gaap	Net Income Loss NetIncomeLoss	89833000
CY2019	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	89833000
CY2018	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-209339000
CY2017	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-238170000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69679916
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65034827
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53133620
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3491272
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2019	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	14755
CY2018	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	0
CY2017	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	0
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	73185943
CY2018	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	65034827
CY2017	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	53133620
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.23
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.22
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.34
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.67
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.48
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14908410
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19261805
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16027317
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37098000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	83433000
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	111684000
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	123856000
CY2019Q1	us-gaap	Gross Profit GrossProfit	34873000
CY2019Q2	us-gaap	Gross Profit GrossProfit	82832000
CY2019Q3	us-gaap	Gross Profit GrossProfit	105237000
CY2019Q4	us-gaap	Gross Profit GrossProfit	116051000
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	53697000
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	55940000
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	59843000
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	78823000
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-20004000
CY2019Q2	us-gaap	Profit Loss ProfitLoss	23567000
CY2019Q3	us-gaap	Profit Loss ProfitLoss	47043000
CY2019Q4	us-gaap	Profit Loss ProfitLoss	39227000
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.32
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.53
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	42032000
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	44910000
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	56972000
CY2018Q4	us-gaap	Operating Expenses OperatingExpenses	60502000
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-44302000
CY2018Q2	us-gaap	Profit Loss ProfitLoss	-43685000
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-58826000
CY2018Q4	us-gaap	Profit Loss ProfitLoss	-62596000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-44297000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-43638000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-58808000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-62596000
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.74
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.92

Files In Submission

Name	View Source	Status
0001564590-20-007416-index-headers.html	Edgar Link	pending
0001564590-20-007416-index.html	Edgar Link	pending
0001564590-20-007416.txt	Edgar Link	pending
0001564590-20-007416-xbrl.zip	Edgar Link	pending
chrs-10k_20191231.htm	Edgar Link	pending
chrs-10k_20191231_htm.xml	Edgar Link	completed
chrs-20191231.xsd	Edgar Link	pending
chrs-20191231_cal.xml	Edgar Link	unprocessable
chrs-20191231_def.xml	Edgar Link	unprocessable
chrs-20191231_lab.xml	Edgar Link	unprocessable
chrs-20191231_pre.xml	Edgar Link	unprocessable
chrs-ex1029_580.htm	Edgar Link	pending
chrs-ex1030_581.htm	Edgar Link	pending
chrs-ex231_9.htm	Edgar Link	pending
chrs-ex311_6.htm	Edgar Link	pending
chrs-ex312_7.htm	Edgar Link	pending
chrs-ex321_8.htm	Edgar Link	pending
chrs-ex43_444.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g1zwbnf3fris000001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CHRS
Coherus BioSciences, Inc. Stock $chrs

2019 Q4 Form 10-K Financial Statement

#000156459020007416 Filed on February 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRS Coherus BioSciences, Inc. Stock $chrs

2019 Q4 Form 10-K Financial Statement

#000156459020007416 Filed on February 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRS
Coherus BioSciences, Inc. Stock $chrs